nach oben

Erschienen in:

28.01.2016 | Interventional

Regional thermochemotherapy versus hepatic arterial infusion chemotherapy for palliative treatment of advanced hilar cholangiocarcinoma: a retrospective controlled study

verfasst von: Yaoting Chen, Huiqing Li, Xiongying Jiang, Dong Chen, Jiayan Ni, Hongliang Sun, Jianghong Luo, Herui Yao, Linfeng Xu

Erschienen in: European Radiology | Ausgabe 10/2016

Einloggen, um Zugang zu erhalten

Abstract

Objectives

To retrospectively assess the efficacy of regional thermochemotherapy (TCT) compared with hepatic arterial infusion chemotherapy (HAIC)-alone for palliative treatment of advanced hilar cholangiocarcinoma (HC) and to determine the prognostic factors associated with survival.

Methods

Forty-three consecutive patients with advanced HC underwent regional TCT (TCT group) and HAIC (HAIC group). We analyzed baseline characteristics, overall survival (OS), progression-free survival (PFS), stent patency time (SPT), adverse events (AEs), and prognostic factors for OS between the two groups.

Results

OS of patients treated with regional TCT was significantly longer compared to that of patients treated with HAIC (median OS: 20.3 vs. 13.2 months, P = 0.004), and SPT and PFS were significantly increased in the TCT group compared with the HAIC group (median SPT: 26.5 vs. 10.5 months, P < 0.001; median PFS: 16.5 vs. 10.2 months, P = 0.001). TCT and metal stent insertion were two independent prognostic factors associated with survival. The treatment-related AEs were tolerable and similar in the two groups, except for hilar pain (34.6 %) and skin rashes (24.6 %) in the TCT group.

Conclusions

Our results show that regional TCT is safe and more effective than HAIC-alone and may be a promising option for palliative treatment of advanced HC. Metal stenting before TCT appears to improve patients’ OS.

Key points

• Regional TCT is a novel combination for palliative treatment of advanced HC

• Our data showed significantly promising outcomes in the TCT group

• HC patients with metal stenting appeared to derive greater benefit from TCT

Deoliveira ML, Schulick RD, Nimura Y et al (2011) New staging system and a registry for perihilar cholangiocarcinoma. Hepatology 53:1363–1371CrossRefPubMed

de Groen PC, Gores GJ, LaRusso NF, Gunderson LL, Nagorney DM (1999) Biliary tract cancers. N Engl J Med 341:1368–1378CrossRefPubMed

de Jong MC, Marques H, Clary BM et al (2012) The impact of portal vein resection on outcomes for hilar cholangiocarcinoma: a multi-institutional analysis of 305 cases. Cancer 118:4737–4747CrossRefPubMed

Cheng JL, Bruno MJ, Bergman JJ, Rauws EA, Tytgat GN, Huibregtse K (2002) Endoscopic palliation of patients with biliary obstruction caused by nonresectable hilar cholangiocarcinoma: efficacy of self-expandable metallic Wallstents. Gastrointest Endosc 56:33–39CrossRefPubMed

Zaydfudim VM, Rosen CB, Nagorney DM (2014) Hilar cholangiocarcinoma. Surg Oncol Clin N Am 23:247–263CrossRefPubMed

Nagino M, Ebata T, Yokoyama Y et al (2013) Evolution of surgical treatment for perihilar cholangiocarcinoma: a single-center 34-year review of 574 consecutive resections. Ann Surg 258:129–140CrossRefPubMed

Valero V 3rd, Cosgrove D, Herman JM, Pawlik TM (2012) Management of perihilar cholangiocarcinoma in the era of multimodal therapy. Expert Rev Gastroenterol Hepatol 6:481–495CrossRefPubMedPubMedCentral

Kobayashi A, Miwa S, Nakata T, Miyagawa S (2010) Disease recurrence patterns after R0 resection of hilar cholangiocarcinoma. Br J Surg 97:56–64CrossRefPubMed

Jarnagin WR, Ruo L, Little SA et al (2003) Patterns of initial disease recurrence after resection of gallbladder carcinoma and hilar cholangiocarcinoma: implications for adjuvant therapeutic strategies. Cancer 98:1689–1700CrossRefPubMed

10.

Rosen CB (2014) Hilar cholangiocarcinoma: no longer hopeless. Dig Dis Sci 59:905–907CrossRefPubMed

11.

Ramirez-Merino N, Aix SP, Cortes-Funes H (2013) Chemotherapy for cholangiocarcinoma: an update. World J Gastrointest Oncol 5:171–176CrossRefPubMedPubMedCentral

12.

Valle J, Wasan H, Palmer DH et al (2010) Cisplatin plus gemcitabine versus gemcitabine for biliary tract cancer. N Engl J Med 362:1273–1281CrossRefPubMed

13.

Yamagami T, Kato T, Iida S, Tanaka O, Nishimura T (2004) Value of transcatheter arterial embolization with coils and n-butyl cyanoacrylate for long-term hepatic arterial infusion chemotherapy. Radiology 230:792–802CrossRefPubMed

14.

Vogl TJ, Zangos S, Eichler K, Selby JB, Bauer RW (2008) Palliative hepatic intraarterial chemotherapy (HIC) using a novel combination of gemcitabine and mitomycin C: results in hepatic metastases. Eur Radiol 18:468–476CrossRefPubMed

15.

Matsumoto S, Kiyosue H, Komatsu E et al (2004) Radiotherapy combined with transarterial infusion chemotherapy and concurrent infusion of a vasoconstrictor agent for nonresectable advanced hepatic hilar duct carcinoma. Cancer 100:2422–2429CrossRefPubMed

16.

Konstantinidis IT, Do RK, Gultekin DH et al (2014) Regional chemotherapy for unresectable intrahepatic cholangiocarcinoma: a potential role for dynamic magnetic resonance imaging as an imaging biomarker and a survival update from two prospective clinical trials Ann Surg Oncol 21:2675–2683

17.

Sticca RP, Dach BW (2003) Rationale for hyperthermia with intraoperative intraperitoneal chemotherapy agents. Surg Oncol Clin N Am 12:689–701CrossRefPubMed

18.

Van der Speeten K, Stuart OA, Sugarbaker PH (2009) Pharmacokinetics and pharmacodynamics of perioperative cancer chemotherapy in peritoneal surface malignancy. Cancer J 15:216–224CrossRefPubMed

19.

Gonzalez-Moreno S, Gonzalez-Bayon LA, Ortega-Perez G (2010) Hyperthermic intraperitoneal chemotherapy: rationale and technique. World J Gastrointest Oncol 2:68–75CrossRefPubMedPubMedCentral

20.

Petryk AA, Giustini AJ, Gottesman RE, Kaufman PA, Hoopes PJ (2013) Magnetic nanoparticle hyperthermia enhancement of cisplatin chemotherapy cancer treatment. Int J Hyperth 29:845–851CrossRef

21.

Chen YT, Yao HR, Xu LF, Sun HL, Teng H (2014) Hepatic arterial infusion chemotherapy combined with endogenetic hyperthermia treatment of hilar cholangiocarcinoma. Hepatogastroenterology 61:151–155

22.

Chen WJ, Ying DJ, Liu ZJ, He ZP (1999) Analysis of the arterial supply of the extrahepatic bile ducts and its clinical significance. Clin Anat 12:245–249CrossRefPubMed

23.

Tohma T, Cho A, Okazumi S et al (2005) Communicating arcade between the right and left hepatic arteries: evaluation with CT and angiography during temporary balloon occlusion of the right or left hepatic artery. Radiology 237:361–365CrossRefPubMed

24.

Eisenhauer EA, Therasse P, Bogaerts J et al (2009) New response evaluation criteria in solid tumours: revised RECIST guideline (version 1.1). Eur J Cancer 45:228–247CrossRefPubMed

25.

25National Comprehensive Cancer Network (NCCN) guidelines in Oncology: Hepatobiliary cancers. V 2. 2012. Available from: www.nccn.org.

26.

Eckmann KR, Patel DK, Landgraf A et al (2011) Chemotherapy outcomes for the treatment of unresectable intrahepatic and hilar cholangiocarcinoma: a retrospective analysis. Gastrointest Cancer Res 4:155–160PubMedPubMedCentral

27.

Laquiere A, Boustiere C, Leblanc S, Penaranda G, Desilets E, Prat F (2015) Safety and feasibility of endoscopic biliary radiofrequency ablation treatment of extrahepatic cholangiocarcinoma. Surg Endosc. doi:10.1007/s00464-015-4322-7

28.

Mosconi C, Renzulli M, Giampalma E et al (2013) Unresectable perihilar cholangiocarcinoma: multimodal palliative treatment. Anticancer Res 33:2747–2753PubMed

29.

Hong MJ, Cheon YK, Lee EJ, Lee TY, Shim CS (2014) Long-term outcome of photodynamic therapy with systemic chemotherapy compared to photodynamic therapy alone in patients with advanced hilar cholangiocarcinoma. Gut Liver 8:318–323CrossRefPubMed

30.

Akiyama S, Kawasaki S, Kodera Y et al (2006) A new method of thermo-chemotherapy using a stent for patients with esophageal cancer. Surg Today 36:19–24CrossRefPubMed

31.

Liu J, Li N, Li L et al (2013) Local hyperthermia for esophageal cancer in a rabbit tumor model: magnetic stent hyperthermia versus magnetic fluid hyperthermia. Oncol Lett 6:1550–1558PubMedPubMedCentral

32.

Zhang F, Le T, Wu X et al (2014) Intrabiliary RF heat-enhanced local chemotherapy of a cholangiocarcinoma cell line: monitoring with dual-modality imaging--preclinical study. Radiology 270:400–408CrossRefPubMedPubMedCentral

33.

Kato H, Kondo M, Imada H et al (2013) Quality assurance: recommended guidelines for safe heating by capacitive-type heating technique to treat patients with metallic implants. Int J Hyperthermia 29:194–205CrossRefPubMed

34.

Goenka MK, Goenka U (2014) Palliation: Hilar cholangiocarcinoma. World J Hepatol 6:559–569PubMedPubMedCentral

35.

Mansour JC, Aloia TA, Crane CH, Heimbach JK, Nagino M, Vauthey JN (2015) Hilar cholangiocarcinoma: expert consensus statement. HPB (Oxford) 17:691–699CrossRefPubMedCentral

36.

Jang SI, Lee DK (2015) Update on Pancreatobiliary Stents: Stent Placement in Advanced Hilar Tumors. Clin Endosc 48:201–208CrossRefPubMedPubMedCentral

Titel: Regional thermochemotherapy versus hepatic arterial infusion chemotherapy for palliative treatment of advanced hilar cholangiocarcinoma: a retrospective controlled study
verfasst von: Yaoting Chen
Huiqing Li
Xiongying Jiang
Dong Chen
Jiayan Ni
Hongliang Sun
Jianghong Luo
Herui Yao
Linfeng Xu
Publikationsdatum: 28.01.2016
Verlag: Springer Berlin Heidelberg
Erschienen in: European Radiology / Ausgabe 10/2016
Print ISSN: 0938-7994
Elektronische ISSN: 1432-1084
DOI: https://doi.org/10.1007/s00330-016-4208-7

Update Radiologie

Bestellen Sie unseren Fach-Newsletter und bleiben Sie gut informiert.

Newsletter bestellen

Springer Medizin

Regional thermochemotherapy versus hepatic arterial infusion chemotherapy for palliative treatment of advanced hilar cholangiocarcinoma: a retrospective controlled study